Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EuCorVac-19 Phase III Immunogenicity and Safety Study
NCT05603052Phase 3Completed
- Sponsor
- EuBiologics
- Start
- Jul 2022
- Primary completion
- Jan 2024
- Modality
- Targeted Liposomes, Recombinant Protein Vaccines, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 3 trial of eucorvac-19 in coronavirus disease 2019 (COVID-19), sponsored by EuBiologics. Started Jul 2022; status: completed.
02
Drugs
eucorvac-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05603052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05603052.